Adults aged 60 and older who received the Shingrix shingles vaccine experienced a 12% lower risk of major cardiovascular events—including heart attacks, strokes, and heart failure—over three and a half years, according to an Oxford University study published in Nature Medicine.
A growing body of scientific research suggests that preventing shingles does more than clear a painful rash; it may also safeguard the heart and brain. In a study tracking the health records of 70,000 adults in the United States, researchers at the University of Oxford investigated the cardiovascular outcomes of patients following vaccination (The Guardian). The findings indicate that recipients of the recombinant shingles vaccine, known commercially as Shingrix, had a 12% reduction in cardiovascular events during the first three and a half years after receiving their shots.
Researchers and epidemiologists point out that while viral infections like shingles can trigger severe inflammation and elevate vascular risks, targeted immunization appears to mitigate those dangers (STAT).
Leveraging a Natural Experiment in US Healthcare Data
Establishing a causal link between vaccines and long-term health outcomes is notoriously difficult because vaccinated individuals often differ from unvaccinated populations in lifestyle, healthcare access, and underlying health. To overcome this limitation, the Oxford research team designed an observational study using a natural experiment (STAT).
They utilized electronic health records from the TriNetX US Collaborative Network, which covers approximately 60 healthcare organizations and more than 100 million patients (Nature). Specifically, the researchers compared matched cohorts of patients who received their shingles vaccinations just six months before or six months after October 2017—the window when the United States rapidly transitioned from the older, live-attenuated vaccine, Zostavax, to the newer recombinant vaccine, Shingrix (STAT).
This design allowed scientists to compare two similar groups receiving vaccines across the same healthcare systems. By tracking 72,000 vaccinated adults aged 60 and older over a seven-year period, the study revealed distinct protective advantages for the newer recombinant technology (STAT).
Breaking Down the Cardiovascular and Neurological Findings
The data demonstrated that Shingrix was associated with measurable reductions across multiple categories of cardiovascular disease. Overall cardiovascular burden dropped by 9%, with coronary heart disease decreasing by 10% and heart failure dropping by 12% in the vaccinated cohort (STAT). Strokes decreased by 12% among men, though the reduction was not statistically significant in women, while atrial fibrillation incidence was 7% lower overall (STAT).
Nevertheless, because heart disease and stroke remain leading causes of death, even a modest individual risk reduction carries significant public health implications (Yahoo News Malaysia).
Lead researcher Dr.
“If confirmed in clinical trials, vaccinating older adults against shingles could prevent hundreds of thousands of coronary heart diseases, strokes and cases of heart failure worldwide, making it one of the most impactful interventions we could offer to protect both the brain and the heart in later life. The effect might be enormous.”
Dr Maxime Taquet, clinical lecturer at the University of Oxford
These cardiovascular findings complement separate, concurrent research streams examining neurological health. A separate study published in the Annals of Internal Medicine analyzed Medicare claims and health records from more than 500,000 adults aged 66 and older admitted to skilled nursing facilities. That analysis found that patients who received Shingrix had a 24% lower risk of a dementia diagnosis over a four-year follow-up period compared to unvaccinated peers (Science Daily).
Exploring Biological Mechanisms and Clinical Trials Ahead
Scientists are still investigating how a vaccine designed to target the varicella-zoster virus might exert protective effects on the heart and brain. One prominent theory is that the virus itself—which remains dormant in nerve tissues after a childhood chickenpox infection—heightens vascular inflammation and increases the risk of stroke and heart attack when reactivated (Nchstats). By preventing shingles more effectively than its predecessor, Shingrix subdues that inflammatory pathway (STAT).
The recombinant vaccine may induce trained immunity, meaning changes in cells of our immune system (STAT).
Despite the promising observational data, researchers stress that definitive proof requires randomized controlled trials (The Guardian).
